CTLA4 and metastatic melanoma: Treatment with ipilimumab, a monoclonal antibody targeting CTLA-4, revealed that the clinical success of T cell immune checkpoint antibodies in patients with metastatic melanoma also relies on off-target effects via myeloid-derived suppressor cells expressing CTLA-4 [30].